

Table S11. Clinical variables and nephrotoxicity

Characteristics	N	Nephrotoxicity		χ^2	p-value	OR	IC _{95%}
		NO N (%)	YES (Grade 1-4) N (%)				
Gender	101						
Female	52	51(98.1)	1(1.9)	-	1*	-	-
Male	49	49(100.0)	0(0.0)				
Age diagnosis PS	101	27.1 (18.3-43.6)	48.8 (48.8-48.8)	-	1*	-	-
Family History of Ps	101						
Yes	52	52 (100.0)	0 (0.0)	-	0.485*	-	-
No	49	48 (98.0)	1 (2.0)				
Smoking	101						
Smoker	31	31 (100.0)	0 (0.0)	-	1*	-	-
Non-smoking	49	48 (92.0)	1 (2.0)				
Former Smoker	21	21 (100.0)	0 (0.0)				
Alcoholic drinking	101						
Drinker	38	38 (100.0)	0 (0.0)	-	1*	-	-
Non-drinker	61	60 (98.4)	1 (1.6)				
Former Drinker	2	2 (100.0)	0 (0.0)				
Type of Psoriasis	101						
Plaque	74	73(98.6)	1(1.4)	-	1*	-	-
Pustular	5	5(100.0)	0(0.0)				
Inverse	1	1(100.0)	0(0.0)				
Guttate	5	5(100.0)	0(0.0)				
Plaque and guttate	12	12(100.0)	0(0.0)				
Plaque and inverse	2	2(100.0)	0(0.0)				
Plaque and pustular	1	1(100.0)	0(0.0)				
Plaque, guttate and inverse	1	1(100.0)	0(0.0)				
Localization							
Trunk and limbs	101						
Yes	93	92 (98.9)	1(1.1)	-	1*	-	-
No	8	8(100.0)	0(0.0)				
Scalp and face	101						
Yes	77	76(98.7)	1(1.3)	-	1*	-	-
No	24	24(100.0)	0(0.0)				
Nails	101						
Yes	58	57(98.3)	1(1.7)	-	1*	-	
No	43	43(100.0)	0(0.0)				
Palmoplantar	101						
Yes	19	19(100.0)	0(0.0)	-	1*	-	-
No	82	81(98.8)	1(1.2)				
Flexures	101						
Yes	28	28 (100.0)	0 (0.0)	-	1*	-	-
No	73	72 (98.6)	1 (1.4)				
Development of PSA	101						
Yes	31	30(96.8)	1(3.2)	-	0.307*	-	-
No	70	70(100.0)	0(0.0)				
Comorbidities							
	101						
Yes	57	56(98.2)	1(1.8)	-	1*	-	-
No	44	44(100.0)	0(0.0)				
Age of onset of MTX	101	45.47±14.81	59.00±0.00	-	1*	-	-

MTX therapy duration (months)	101	14.5 (5.0-31.5)	144.0 (144.0-144.0)	-	1*	-	-
MTX Administration	101						
Oral	47	47 (100.0)	0 (0.0)	-	0.238*	-	-
Subcutaneous	30	30 (100.0)	0 (0.0)				
Both	24	23 (95.8)	1 (4.2)				
Type of MTX therapy	101						
Monotherapy	93	93 (100.0)	0 (0.0)	-	0.079*	-	-
Combination Therapy	8	7 (87.5)	1 (12.5)				
Maximum MTX dose (mg/week)	101	12.5 (10.0-15.0)	20.0 (20.0-20.0)	-	1*	-	-
Therapeutic adherence							
Adherent	70	70 (100.0)	0 (0.0)	-	0.307*	-	-
Intentional non-adherent	30	29 (96.7)	1 (3.3)				
Unintentional non-adherent	1	1 (100.0)	0 (0.0)				

*p-value for the Fisher's test. PS: psoriasis; PSA: psoriatic arthritis.